GO:0047822 hypotaurine monooxygenase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0047822 (hypotaurine monooxygenase activity) catalyzes the NADPH- and O2-dependent oxidation of hypotaurine to taurine, a critical step in taurine biosynthesis.
• The reaction consumes H+, hypotaurine, NADPH, and O2 and produces H2O, NADP+, and taurine, linking this activity to cellular redox and sulfur metabolism.
• Taurine produced by this activity is essential for bile acid conjugation, osmoregulation, retinal function, and cardiovascular health.
• The enzyme belongs to the flavin-containing monooxygenase (FMO) family, with FMO1 and FMO3 being leading candidates for hypotaurine monooxygenase activity in mammals [1,3].
• Dysregulation of taurine synthesis has been implicated in liver injury, metabolic disorders, and neurological conditions [1,6].
• CRISPR knockout, point mutation, knock-in, and overexpression models enable precise dissection of GO:0047822 in health and disease.
Description
Hypotaurine monooxygenase activity (GO:0047822) is a molecular function that catalyzes the final step in taurine biosynthesis: the oxidation of hypotaurine to taurine. Taurine (2-aminoethanesulfonic acid) is one of the most abundant free amino acids in mammals and plays pleiotropic roles in bile acid conjugation, osmoregulation, calcium signaling, retinal development, and antioxidant defense. The enzyme responsible for this activity has been sought for decades, and recent work has identified a novel enzyme and regulatory mechanisms in mammalian taurine synthesis. Understanding GO:0047822 is therefore central to sulfur amino acid metabolism and its associated pathologies. The reaction requires NADPH and molecular oxygen and produces NADP+ and water, classifying this activity as a monooxygenase. In mammals, flavin-containing monooxygenases (FMOs), particularly FMO1 and FMO3, have been implicated in hypotaurine oxidation, though the exact enzyme identity remains an active area of research [1,3]. The hydroperoxyflavin intermediate of human FMO1 has been structurally characterized, providing mechanistic insight into how such enzymes activate molecular oxygen. This article synthesizes current knowledge on GO:0047822, its genes, regulation, disease links, and experimental approaches, with a focus on CRISPR-based models for functional validation.
hypotaurine monooxygenase activity At A Glance
| GO ID | GO:0047822 |
|---|---|
| GO term | hypotaurine monooxygenase activity |
| Ontology | molecular_function |
| Synonym | hypotaurine dehydrogenase activity |
| Definition | Catalysis of the reaction: H+ + hypotaurine + NADPH + O2 = H2O + NADP+ + taurine. |
| Major function | Final step of taurine biosynthesis; sulfur amino acid metabolism |
| Cofactors | NADPH, FAD (likely, based on FMO family) [1,3] |
| Subcellular location | Cytosol (predicted for FMO family) |
| Pathway | Taurine and hypotaurine metabolism |
What Is GO:0047822?
Hypotaurine monooxygenase activity (GO:0047822) is defined as the catalysis of the reaction: H+ + hypotaurine + NADPH + O2 = H2O + NADP+ + taurine. In other words, it is an oxidoreductase activity that uses NADPH as an electron donor and molecular oxygen as an oxygen atom donor to convert hypotaurine into taurine, releasing water and NADP+. The term is synonymous with hypotaurine dehydrogenase activity, although the reaction mechanism is monooxygenase-type rather than a simple dehydrogenase.
Why Is hypotaurine monooxygenase activity Important in Cell Biology?
GO:0047822 is important because it governs the terminal step of taurine biosynthesis, and taurine is indispensable for numerous physiological processes including bile acid conjugation, osmoregulation, antioxidant defense, retinal and cardiac function, and neurodevelopment. Disruption of taurine synthesis has been linked to liver injury, metabolic syndrome, and neurological dysfunction [1,6]. Moreover, the enzyme catalyzing this activity is a potential therapeutic target for conditions characterized by taurine deficiency. Understanding its regulation and catalytic mechanism can inform nutritional and pharmacological strategies to modulate taurine levels.
• Taurine is essential for bile acid conjugation and fat absorption.
• Taurine acts as an osmolyte, protecting cells from osmotic stress.
• Taurine has antioxidant properties and protects against oxidative damage.
• Taurine is critical for retinal photoreceptor development and survival.
• Taurine supports cardiovascular function and calcium handling.
• Dysregulated taurine synthesis is associated with liver disease and metabolic disorders [1,6].
• GO:0047822 links sulfur amino acid metabolism to redox homeostasis.
• The enzyme is a candidate target for modulating taurine levels in disease.
• CRISPR models enable causal testing of GO:0047822 in vivo.
Molecular Mechanism of hypotaurine monooxygenase activity
Substrate Binding and Oxygen Activation
In simple terms: The enzyme grabs hypotaurine and uses oxygen to modify it.
Hypotaurine monooxygenase activity begins with the binding of hypotaurine and NADPH to the enzyme active site. The enzyme, likely a flavin-containing monooxygenase (FMO), utilizes FAD as a prosthetic group to activate molecular oxygen, forming a hydroperoxyflavin intermediate. This intermediate is highly reactive and capable of oxygenating the substrate. The reaction consumes one proton, hypotaurine, NADPH, and O2, and produces water, NADP+, and taurine.
Catalytic Cycle and Product Release
In simple terms: The enzyme transfers an oxygen atom to hypotaurine, turning it into taurine.
Following oxygen activation, the hydroperoxyflavin intermediate transfers an oxygen atom to hypotaurine, yielding taurine and water. NADPH is oxidized to NADP+ in the process. The catalytic cycle of FMOs involves NADPH-dependent reduction of FAD, reaction with oxygen to form the hydroperoxyflavin, substrate oxygenation, and release of products. The hydroperoxyflavin intermediate of human FMO1 has been structurally characterized, providing a framework for understanding this mechanism.
Enzyme Identity and Isoforms
In simple terms: Several enzymes might do this job, and scientists are still identifying the main one.
The exact enzyme responsible for hypotaurine monooxygenase activity in mammals has been debated. Recent work identified a novel enzyme and regulatory mechanisms in mammalian taurine synthesis. FMO1 and FMO3 are leading candidates due to their ability to oxidize sulfur-containing compounds [1,3]. FMO1 is expressed in kidney, liver, and other tissues, while FMO3 is prominent in liver. Their differential expression may contribute to tissue-specific taurine synthesis.
Cofactors and Cofactor Regeneration
In simple terms: The enzyme needs helper molecules (NADPH and FAD) to work.
The reaction requires NADPH as an electron donor and FAD as a prosthetic group. NADPH is oxidized to NADP+, and the resulting NADP+ must be reduced back to NADPH by cellular pathways such as the pentose phosphate pathway. FAD is tightly bound to the enzyme and cycles between oxidized and reduced states during catalysis [1,3].
Regulation of Enzyme Activity
In simple terms: The cell can turn this enzyme up or down depending on its needs.
Hypotaurine monooxygenase activity is likely regulated at multiple levels, including enzyme expression, substrate availability, and redox state. The novel enzyme identified in mammalian taurine synthesis is subject to regulation, as are key enzymes in the pathway. Additionally, FMO enzymes can be regulated by hormones, xenobiotics, and dietary factors. However, specific regulatory mechanisms for GO:0047822 remain to be fully elucidated.
Key Genes Involved in GO:0047822 hypotaurine monooxygenase activity
The following genes and proteins are implicated in hypotaurine monooxygenase activity or related taurine biosynthetic pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FMO1 | Flavin-containing monooxygenase 1; candidate enzyme for hypotaurine oxidation | Hydroperoxyflavin intermediate characterized; potential knockout target |
| FMO3 | Flavin-containing monooxygenase 3; candidate enzyme for hypotaurine oxidation | Liver-enriched; linked to trimethylaminuria; potential knockout target |
| FMO2 | Flavin-containing monooxygenase 2 | Expressed in lung; may contribute to sulfur oxidation |
| FMO4 | Flavin-containing monooxygenase 4 | Less characterized; potential redundancy |
| FMO5 | Flavin-containing monooxygenase 5 | Metabolic roles; not directly linked to taurine synthesis |
| CDO1 | Cysteine dioxygenase 1; converts cysteine to cysteine sulfinic acid | Upstream of hypotaurine synthesis |
| CSAD | Cysteine sulfinic acid decarboxylase; produces hypotaurine | Direct upstream enzyme; knockout reduces taurine |
| GADL1 | Glutamate decarboxylase-like 1; alternative hypotaurine synthesis | May compensate in CSAD deficiency |
| SLC6A6 | Taurine transporter | Regulates taurine uptake; knockout causes taurine depletion |
| CBS | Cystathionine beta-synthase; transsulfuration | Provides cysteine for taurine synthesis |
| CTH | Cystathionine gamma-lyase; transsulfuration | Provides cysteine for taurine synthesis |
| MAT1A | Methionine adenosyltransferase; SAM synthesis | Indirect role in sulfur metabolism |
| GCLC | Glutamate-cysteine ligase catalytic subunit | Glutathione synthesis; affects cysteine availability |
| GCLM | Glutamate-cysteine ligase modifier subunit | Glutathione synthesis; affects cysteine availability |
| NQO1 | NAD(P)H quinone dehydrogenase 1 | Redox balance; may affect NADPH levels |
| G6PD | Glucose-6-phosphate dehydrogenase | Generates NADPH for the reaction |
| IDH1 | Isocitrate dehydrogenase 1 | Generates NADPH for the reaction |
| IDH2 | Isocitrate dehydrogenase 2 | Generates NADPH for the reaction |
How Is hypotaurine monooxygenase activity Regulated?
Hypotaurine monooxygenase activity is regulated by the expression and activity of the responsible enzyme(s), substrate availability, and cellular redox state. The novel enzyme identified in mammalian taurine synthesis is subject to regulation, as are key enzymes in the pathway. FMO enzymes can be induced or inhibited by various xenobiotics and hormones, but specific regulatory mechanisms for GO:0047822 require further study. NADPH supply from the pentose phosphate pathway and isocitrate dehydrogenases may also influence flux through this reaction.
hypotaurine monooxygenase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FMO1 | Taurine deficiency; liver injury | Fmo1 knockout mouse; hepatocyte-specific KO [1,3] |
| FMO3 | Trimethylaminuria; metabolic disorders | Fmo3 knockout mouse; liver overexpression |
| CSAD | Taurine deficiency; retinal degeneration | Csad knockout mouse; knock-in of human variant |
| SLC6A6 | Taurine transporter deficiency; cardiomyopathy | Slc6a6 knockout mouse; cardiac-specific KO |
| CDO1 | Cysteine metabolism disorders | Cdo1 knockout mouse; liver-specific KO |
Liver Injury and Metabolic Disorders
Taurine deficiency has been linked to acute ethanol-induced liver injury, and betaine supplementation alleviates this by restoring S-containing metabolites including taurine. Hypotaurine monooxygenase activity, by producing taurine, may protect against liver damage. Dysregulation of this activity could contribute to metabolic disorders characterized by altered sulfur amino acid metabolism [1,6].
Neurological and Neurodegenerative Conditions
Taurine is important for brain development and function, acting as an inhibitory neurotransmitter and neuroprotectant. Altered taurine levels have been observed in Alzheimer's disease models, and metabolomic studies of plant extracts against Alzheimer's disease have highlighted taurine pathway changes. Deficiencies in taurine synthesis may exacerbate neurodegeneration.
Cardiovascular and Retinal Diseases
Taurine is essential for cardiac function and retinal photoreceptor survival. Mice lacking taurine transporter SLC6A6 develop retinal degeneration and cardiomyopathy. Reduced hypotaurine monooxygenase activity could lead to taurine depletion and contribute to these pathologies.
From hypotaurine monooxygenase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does FMO1 catalyze hypotaurine oxidation in vivo? | Fmo1 knockout mouse; liver-specific KO [1,3] |
| Does FMO3 contribute to taurine synthesis? | Fmo3 knockout mouse; overexpression |
| What is the effect of a point mutation in the active site? | CRISPR point mutation knock-in in cell lines |
| Can tagged FMO1 reveal subcellular localization? | Knock-in of FLAG/GFP tag at endogenous locus |
| Does CSAD deficiency alter taurine levels? | Csad knockout mouse; metabolomics |
| Can overexpression rescue taurine deficiency? | Transgenic overexpression of FMO1 or FMO3 |
How to Study the hypotaurine monooxygenase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS metabolomics | Hypotaurine and taurine levels | Quantify pathway flux in cells/tissues [2,4,8] |
| Enzymatic activity assay | NADPH consumption or taurine production | Measure GO:0047822 in vitro [1,3] |
| CRISPR knockout screen | Gene essentiality for taurine synthesis | Identify novel pathway genes |
| RNA-seq | Expression of FMO isoforms and pathway genes | Tissue-specific expression profiling |
| Proteomics | Protein abundance and modifications | Validate enzyme candidates |
| Immunofluorescence | Subcellular localization | Determine organelle targeting |
| Stable isotope tracing | Flux from hypotaurine to taurine | Quantify pathway activity in vivo |
| Rapid kinetics | Hydroperoxyflavin intermediate | Mechanistic studies of FMO1 |
Metabolomics and Taurine Quantification
Targeted metabolomics using UHPLC-Orbitrap-Fusion-TMS or LC-MS/MS can quantify hypotaurine and taurine levels in cells and tissues [2,4,8]. These methods are essential to measure flux through GO:0047822. Stable isotope labeling with 13C or 15N can trace hypotaurine conversion to taurine.
Enzymatic Activity Assays
In vitro assays using recombinant FMO enzymes, hypotaurine, NADPH, and oxygen can directly measure hypotaurine monooxygenase activity. NADPH consumption or taurine production can be monitored spectrophotometrically or by HPLC [1,3]. The hydroperoxyflavin intermediate can be trapped and characterized by rapid kinetics.
CRISPR Screening and Functional Genomics
Genome-wide CRISPR knockout screens can identify genes required for taurine synthesis. Cells lacking candidate enzymes can be supplemented with taurine to assess auxotrophy. Pooled screens with taurine-free media can enrich for sgRNAs targeting essential genes.
Proteomics and Expression Analysis
Quantitative proteomics and RNA-seq can measure expression of FMO isoforms and other taurine pathway genes across tissues and conditions. Immunoblotting and immunofluorescence can localize the enzyme.
How CRISPR Can Be Used to Study GO:0047822 hypotaurine monooxygenase activity
Knockout
CRISPR knockout of candidate genes such as FMO1, FMO3, or CSAD can abolish hypotaurine monooxygenase activity, leading to taurine depletion. These models are valuable for assessing the contribution of each enzyme to taurine synthesis and for studying downstream physiological effects.
Point Mutation
Point mutations in the active site of FMO enzymes can be introduced to dissect catalytic residues involved in oxygen activation and substrate binding. For example, mutating the NADPH-binding motif or the FAD-binding site can clarify mechanism. Such models help validate the hydroperoxyflavin intermediate.
Knock-in
Knock-in of epitope tags (e.g., FLAG, GFP) at the endogenous locus allows visualization and immunoprecipitation of the enzyme. Knock-in of human disease-associated variants can model their impact on taurine synthesis. This approach preserves endogenous regulation.
Overexpression
Overexpression of FMO1 or FMO3 in cell lines or transgenic animals can increase hypotaurine monooxygenase activity and taurine production. This is useful for rescue experiments and for testing whether increased taurine protects against disease. Overexpression models also help identify rate-limiting steps.
How EDITGENE Supports hypotaurine monooxygenase activity Research
Researchers studying hypotaurine monooxygenase activity-related genes often need to determine whether a candidate gene is causally involved in taurine synthesis and whether its manipulation alters disease phenotypes. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell and animal models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for hypotaurine monooxygenase activity research.
Frequently Asked Questions About hypotaurine monooxygenase activity
What is hypotaurine monooxygenase activity?
Hypotaurine monooxygenase activity (GO:0047822) is the enzyme activity that catalyzes the conversion of hypotaurine to taurine using NADPH and oxygen, producing NADP+ and water.
What genes are involved in hypotaurine monooxygenase activity?
Candidate genes include FMO1, FMO3, and other flavin-containing monooxygenases, as well as upstream pathway genes like CSAD and CDO1 [1,3].
What is the reaction catalyzed by GO:0047822?
The reaction is: H+ + hypotaurine + NADPH + O2 = H2O + NADP+ + taurine.
Which diseases are linked to hypotaurine monooxygenase activity?
Taurine deficiency resulting from reduced activity has been linked to liver injury, metabolic disorders, retinal degeneration, and cardiomyopathy [1,6].
How can I study hypotaurine monooxygenase activity in the lab?
You can use enzymatic assays, metabolomics, and CRISPR knockout models targeting FMO1 or FMO3 [1,3].
What are the synonyms for GO:0047822?
The synonym is hypotaurine dehydrogenase activity.
Is hypotaurine monooxygenase activity the same as taurine synthesis?
It is the final step of taurine synthesis, but taurine can also be obtained from diet or other pathways.
What cofactors are required for hypotaurine monooxygenase activity?
NADPH and FAD are required; NADPH provides electrons and FAD activates oxygen [1,3].
Can CRISPR be used to study hypotaurine monooxygenase activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect the function of candidate genes.
What cell models are available for taurine research?
EDITGENE provides custom knockout, point mutation, knock-in, and overexpression cell models for taurine pathway genes.
Conclusion
Hypotaurine monooxygenase activity (GO:0047822) is a critical molecular function in taurine biosynthesis, with broad implications for liver, cardiovascular, retinal, and neurological health. Although the exact enzyme identity remains under investigation, FMO1 and FMO3 are strong candidates. CRISPR-based models offer unprecedented opportunities to validate gene function and explore therapeutic targeting of this pathway. EDITGENE's comprehensive services support researchers in generating precise models to study GO:0047822 and its role in disease.
References
- 1. Miyazaki T. 2024. Identification of a novel enzyme and the regulation of key enzymes in mammalian taurine synthesis.. J Pharmacol Sci 154(1):9-17 PMID: 38081683
- 2. Wu DD et al.. 2023. UHPLC-Orbitrap-Fusion-TMS-Based Metabolomics Study of Phenylpropionamides in the Seed of Cannabis sativa L. against Alzheimer's Disease.. Chem Biodivers 20(5):e202201047 PMID: 37072341
- 3. Cheropkina H et al.. 2021. Human flavin-containing monooxygenase 1 and its long-sought hydroperoxyflavin intermediate.. Biochem Pharmacol 193:114763 PMID: 34509493
- 4. Zhu H et al.. 2022. An integrated network pharmacology and metabolomics approach to reveal the immunomodulatory mechanism of Brassica rapa L. (Tibetan Turnip) in fatigue mice.. Food Funct 13(21):11097-11110 PMID: 36200535
- 6. Kim SJ et al.. 2008. Alleviation of acute ethanol-induced liver injury and impaired metabolomics of S-containing substances by betaine supplementation.. Biochem Biophys Res Commun 368(4):893-8 PMID: 18267108
- 8. Leng X et al.. 2025. [Effects of ginsenoside Rb_1 on liver FXR pathway and liver and fecal bile acid profiles in rats induced by high-fat diet based on targeted metabolomics].. Zhongguo Zhong Yao Za Zhi 50(16):4649-4658 PMID: 41084479
